Statins and Type 2 Diabetes: Understanding the Risks and Benefits
DiabetesType 2 Diabetes

How Statins May Affect Type 2 Diabetes Progression

How Statins May Affect Type 2 Diabetes Progression
Anna Bergbauer/iStock; Adobe Stock; Everyday Health
By
Updated on January 30, 2026
by

Statins are often prescribed to manage cholesterol and treat heart disease, but research suggests these medications may pose certain risks for people with type 2 diabetes. Because type 2 diabetes is a risk factor for heart disease, people with high cholesterol may want to talk to their doctor about the benefits of taking statins and the medication’s risks.

Type 2 Diabetes Risk Factors

Type 2 Diabetes Risk Factors
Type 2 Diabetes Risk Factors

Next up video playing in 10 seconds

The Link Between Statins and Type 2 Diabetes

Available by prescription only, statins work by lowering the amount of cholesterol the liver produces. They help reduce low-density lipoprotein (LDL) cholesterol, or bad cholesterol, and may raise high-density lipoprotein (HDL) cholesterol, or good cholesterol. Statins also decrease inflammation in and reduce plaque buildup on the artery walls and lower the chances of blood clot formation.

For these reasons, statins reduce the risk of heart disease, the leading cause of death for people in the United States. That’s especially important for people with type 2 diabetes, who are twice as likely to have heart disease or a stroke than people without diabetes.

However, statins may affect how the pancreas produces and releases insulin as well as how the body uses it. Insulin resistance can cause type 2 diabetes.

One retrospective study found 56 percent of participants on statins experienced diabetes progression, including dangerous spikes in blood sugar or the need for new medications to manage blood sugar, compared with 48 percent of people who didn’t use statins. Participants on more intensive statin therapy designed to reduce cholesterol levels more aggressively had an 83 percent greater likelihood of diabetes progression.

Additional research suggests statin treatment, especially in higher doses, can increase insulin resistance and insulin secretion.

“Why this happens isn’t fully understood,” says Stephanie J. Kim, MD, MPH, an endocrinologist at UW Medicine in Seattle.

Insulin helps move glucose from your blood into your cells so your body can use it for energy. When the body doesn’t respond to insulin properly, glucose can build up in the blood. Elevated blood-glucose levels, called hyperglycemia, can occur if the pancreas can’t make enough insulin to compensate for this insulin resistance, leading to prediabetes and type 2 diabetes.

Genetic makeup also affects how statins work. A variation of the SLCO1B1 gene can prevent statins from entering the liver properly and cause them to build up in the blood, potentially leading to muscle problems, weakness, and pain.

People who are genetically resistant to statins also may also see little improvement in their cholesterol.

Types of Statins and How They Affect Diabetes Risk

Statin intensity is based on the amount that the statin lowers LDL cholesterol and at what strength, which is classified as high, moderate, or low intensity. The higher the intensity, the more the statin lowers LDL cholesterol.

Here’s how statin dosage is classified:

Statin
High intensity (lowers LDL at least 50 percent)
Moderate intensity (lowers LDL 30 to 49 percent)
Low intensity (lowers LDL less than 30 percent)
atorvastatin (Lipitor)
40–80 mg
10–20 mg
N/A
fluvastatin (Lescol)
N/A
40 mg twice per day; XL 80 mg
20–40 mg
lovastatin
N/A
40–80 mg
20 mg
pitavastatin
N/A
1–4 mg
N/A
pravastatin
N/A
40–80 mg
10–20 mg
rosuvastatin (Crestor)
20–40 mg
5–10 mg
N/A
simvastatin (Zocor)
N/A
20–40 mg
10 mg
A meta-analysis of randomized controlled trials that included 149,000 people found a dose-dependent relationship: The higher the dose or more potent the statin, the greater the risk for people developing type 2 diabetes.

“Statin use at a high intensity seems to increase markers of glucose control, such as hemoglobin A1C levels, and can lead to a higher incidence of type 2 diabetes if you’re already at risk for diabetes,” says Ashish Sarraju, MD, cardiologist at Cleveland Clinic in Ohio.

Benefits and Risks of Statins for People With Diabetes

Not everyone who takes a statin will develop type 2 diabetes, says Dr. Kim.

“For people who are at high risk of cardiovascular disease, the benefits of statins in reducing their risk of heart attacks, strokes, and other cardiovascular events usually outweigh the potential risk of developing diabetes,” she says.

In addition to speaking with your doctor, you can check your risk for cardiovascular disease with the American College of Cardiology’s risk estimator tool.

Data may suggest that statin risks are greater among people already at risk of type 2 diabetes, says Dr. Sarraju. These risk factors can include elevated glucose levels, high triglycerides, and obesity.

“For people who are not in this situation, the excess risk of diabetes with statins is likely very low and negligible in many cases,” he says.

When talking to patients about high-intensity statin doses and type 2 diabetes, Sarraju says he discusses the data behind the correlation. He also notes other ways to mitigate the risk of type 2 diabetes, including exercising, improving diet, and losing weight.

“Statin therapies reduce risk even in patients with diabetes, so on the whole, if there is a strong indication for statins, the benefits are more likely to outweigh the risks,” says Sarraju.

The Takeaway

  • While statins are effective at lowering LDL cholesterol and reducing the risk of heart disease, research indicates they may also increase insulin resistance and negatively affect how the body processes blood sugar.
  • Studies show a dose-dependent relationship between statin use and diabetes, with high-intensity statin therapy being significantly more likely to cause diabetes progression or dangerous spikes in blood sugar than lower doses.
  • People already at risk for type 2 diabetes, such as those with obesity or high triglycerides, face the highest risk of worsening their condition while on statins, whereas the risk for others is considered negligible.
  • Despite these concerns, medical experts generally agree that the benefits of statins in preventing life-threatening strokes and heart attacks typically outweigh the potential risk of developing or worsening diabetes.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Statins. Cleveland Clinic. March 12, 2024.
  2. Statins and Diabetes: What You Should Know. Centers for Disease Control and Prevention. May 15, 2024.
  3. Mansi IA et al. Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. JAMA Internal Medicine. October 4, 2021.
  4. Chase A. Understanding How Statins Prevent Cardiovascular Disease but Increase Diabetes Risk. Stanford Medicine. January 3, 2022.
  5. Insulin Resistance. Cleveland Clinic. November 21, 2024.
  6. Pharmacogenomics. Centers for Disease Control and Prevention. November 13, 2024.
  7. Dabiri H et al. Genome-Wide Association Study of Therapeutic Response to Statin Drugs in Cardiovascular Disease. Scientific Reports. August 3, 2024.
  8. Cannon CP. Understanding Statin Intensity. Harvard Health Publishing. July 1, 2023.
  9. Chou R et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality. August 2022.
  10. Reith C et al. Effects of Statin Therapy on Diagnoses of New-Onset Diabetes and Worsening Glycaemia in Large-Scale Randomised Blinded Statin Trials: An Individual Participant Data Meta-Analysis. The Lancet Diabetes & Endocrinology. May 2024.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
Anna-L-Goldman-bio

Anna L. Goldman, MD

Medical Reviewer
Castle Connolly Top Doctor

Anna L. Goldman, MD, is a board-certified endocrinologist. She teaches first year medical students at Harvard Medical School and practices general endocrinology in Boston.

Dr. Goldman attended college at Wesleyan University and then completed her residency at Icahn School of Medicine at Mount Sinai Hospital in New York City, where she was also a chief resident. She moved to Boston to do her fellowship in endocrinology at Brigham and Women's Hospital. She joined the faculty after graduation and served as the associate program director for the fellowship program for a number of years.

See full bio
Becky Upham, MA

Becky Upham

Author

Becky Upham has worked throughout the health and wellness world for over 25 years. She's been a race director, a team recruiter for the Leukemia and Lymphoma Society, a salesperson for a major pharmaceutical company, a blogger for Moogfest, a communications manager for Mission Health, a fitness instructor, and a health coach.

Upham majored in English at the University of North Carolina and has a master's in English writing from Hollins University.

Upham enjoys teaching cycling classes, running, reading fiction, and making playlists.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network